1-3 of 3
Helen Guo
Close
Sort by
Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4156–4158.
https://doi.org/10.1182/blood-2022-167213
Published: 2022
Journal Articles

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2999.
https://doi.org/10.1182/blood-2021-147449
Published: 2021
Journal Articles

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

James K R Stevenson, MD MSc, Lucy Qiao, MS, MPH, Kelvin Chan, MD PhD, Jaclyn Beca, MSc, Wanrundee Isaranuwatchai, PhD, Helen Guo, BS, Deborah Schwarz, PhD, Jessica Arias, BA, MACP, Scott Gavura, BSPharm, MBA, C. Tom Kouroukis, MDMSc,FRCPC, Matthew Cheung, MD MS, FRCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 1557.
https://doi.org/10.1182/blood.V130.Suppl_1.1557.1557
Published: 2017